Polymorphisms pharmacogenetic loci

Urano, W., Taniguchi, A., Yamanaka, H., et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 12, 183-190. 

Nebert DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991 1 (2) 68—78. 

Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the TaqlA locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000 l0f4) 335 41. 

Chang, C., D.R. Smith, VS. Prasad, C.L. Sidman, D.W. Nebert, and A. Puga (1993). Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics 3, 312-321. 

Imai J, leiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients Genetic analysis of the CYP2C9 locus. Pharmacogenetics 10(1), 85-89,2000. 

---